Cardiac Events in Adults Hospitalized for Respiratory Syncytial Virus vs COVID-19 or Influenza

作者：Liang En Wee, Jue Tao Lim, Rth Ho, Calvin J. Chiew, David Chien Lye, Kelvin Bryan Tan · 发表于：JAMA Network Open · 年份：2025 · DOI：10.1001/jamanetworkopen.2025.11764 · 被引用次数：20 · 研究领域：Respiratory viral infections research、COVID-19 Clinical Research Studies、SARS-CoV-2 and COVID-19 Research

Importance: Respiratory viral infections (RVIs) are associated with elevated cardiovascular risk; however, less is known about cardiac complications after hospitalization for respiratory syncytial virus (RSV) vs other vaccine-preventable RVIs (COVID-19 or influenza). Objective: To compare the risk of acute cardiovascular complications in adults hospitalized for RSV vs COVID-19 or influenza. Design, Setting, and Participants: This population-based cross-sectional study, conducted before RSV vaccination rollout in Singapore, assessed all adults hospitalized for RSV or influenza (January 1, 2017, to June 30, 2024) and all adults hospitalized for COVID-19 during Omicron XBB/JN.1 transmission (January 1, 2023, to June 30, 2024). Exposure: Hospitalization for RSV, influenza (vaccinated or unvaccinated), or COVID-19 (boosted [≥3 vaccine doses] or unboosted [<3 vaccine doses]). Main Outcomes and Measures: Cardiovascular events during RSV, influenza, or COVID-19 hospitalization, defined as any cardiac, cerebrovascular, or thrombotic event, occurring from admission until discharge or death. Odds of any cardiovascular event (RSV vs COVID-19 or RSV vs influenza) and severe RVI (intensive care unit admission) with or without an acute cardiovascular event were estimated using multivariate logistic regression, adjusted for sociodemographic and clinical characteristics. Results: A total of 32 960 RVI hospitalizations (mean [SD] patient age, 66.58 [18.99] years; 17 056 [51.7%] female) were in...